Do 340B Contract Pharmacies Really 'Increase Access' for 340B Patients?
IQVIA2026-01-1714 页
国金证券研究所2026-01-2421 页
The Obesity Evolution: Refining our Global Anti-Obesity Medication (AOM) Market Model: Oral Options and OUS Poised to Capture Volumes
Goldman Sachs2026-06-0327 页
Preliminary findings from the first cycle of Public Health Emergency Preparedness Assessments – Interim report, June 2026
European Centre for Disease Prevention and Control (ECDC)2026-06-2132 页
Pan-Euro Pharma Primer: 'protein strangling' (ATTR): why should AZN lead in this $20bn peak cardio market?
Bernstein (Sanford C. Bernstein)2026-07-0638 页
Longitudinal Access and Adjudication Data (LAAD) — Product Definition
IQVIA2026-07-168 页